REGENXBIO Inc. Chief Financial Officer Mitchell Chan filed a Form 4 on November 3, 2026, disclosing the acquisition of 24,305 shares of common stock underlying a time-based restricted stock unit award, with a transaction date of November 1, 2026.

Key Highlights

  • RSU award granted: Mitchell Chan, Chief Financial Officer, acquired 24,305 shares of common stock underlying a time-based RSU award on November 1, 2026, at a price of $0.00.
  • Vesting schedule: According to the filing, 1/3rd of the shares vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, subject to continuous service to the issuer.
  • Beneficial ownership following transaction: Chan directly holds 147,120 shares of common stock following the reported transaction.
  • Transaction code: The transaction is coded "A" (acquisition) in Table I of the filing.
  • No cash consideration: The shares were acquired at $0.00, consistent with an RSU grant rather than an open-market purchase.

REGENXBIO CFO Mitchell Chan Receives Time-Based RSU Award

According to the Form 4 filed with the SEC on November 3, 2026, Mitchell Chan, serving as Chief Financial Officer of REGENXBIO Inc. (NASDAQ:RGNX), received a grant of 24,305 shares of common stock in the form of a time-based restricted stock unit award. The transaction date is listed as November 1, 2026, and the shares were acquired at a price of $0.00, as is typical for RSU awards. The filing was signed by Patrick J. Christmas as attorney-in-fact on November 3, 2026.

The filing discloses that the RSU award will vest in equal installments of 1/3rd on each of November 1, 2027, November 1, 2028, and November 1, 2029, provided that Chan maintains continuous service to REGENXBIO during that period. No shares from this award will be delivered before the first vesting date in November 2027. Following the reported transaction, Chan's direct beneficial ownership of REGENXBIO common stock stands at 147,120 shares, as stated in Table I of the filing.

The Form 4 reflects no derivative securities activity in Table II, and the filing indicates it was made by one reporting person. Chan's address on record is listed as c/o REGENXBIO Inc., 9804 Medical Center Drive, Rockville, Maryland 20850.

What Was Disclosed

REGENXBIO CFO Mitchell Chan disclosed the receipt of a 24,305-share RSU award on November 1, 2026, vesting in three equal annual installments beginning November 1, 2027, with resulting direct beneficial ownership of 147,120 shares.